Medincell Stock Drops Nearly 3% and Slips to the Lower End of the SBF 120
The biotech company from Montpellier experiences another downturn during the session, contrary to an almost stagnant broader index. The stock continues its decline to the lower end of the SBF 120, following the erosion that began earlier in the week. The decline occurs in a market environment strained by renewed tensions in the Middle East and a surge in Brent crude prices.
A Decline Anchoring at the Tail End of the SBF 120 Despite Well-Oriented Moving Averages
Medincell's stock drops 2.92% to €27.92, ranking among the largest declines in the SBF 120 while the broader index edges up by 0.16%. The stock erases part of the rebound that began in late June, with a weekly decline of 4.65%, yet still holds a gain of 26.91% over three months. Despite today's slide, the price remains above its three moving averages, with a gap of 2.99% over the MM20 (€27.11) and 3.71% over the MM50 (€26.92). The RSI at 56 remains in the neutral zone, indicating no immediate pressure. The session unfolds in a market context weighed down by renewed tensions between the United States and Iran, with Brent crude jumping about 5.2% to $78.02 and the CAC 40 slightly up by 0.22%. The stock once again encounters resistance at the €29.56 mark, a barrier identified and unsuccessfully tested last week. The support at €24.08 remains more than 13% away, providing a cushion before any adverse technical signal.
Uzedy Royalties Pivot, Awaiting the Launch of Olanzapine LAI in Q4 2026
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Fundamentally, today's movement follows the announcement of the annual accounts for 2025/2026 revealed on June 16, which triggered a 13.5% drop at the opening the next day. Uzedy royalties (risperidone) had increased by 42% to €9.3 million, but the net loss had deepened to €31.3 million from €18.4 million a year earlier, reflecting accelerated R&D expenses. Among the opportunities highlighted in the June 16, 2026 publication, the company pointed to the commercial launch of Olanzapine LAI expected in the fourth quarter of 2026 and the continued increase in Uzedy royalties. Among the risks identified were the absence of exceptional revenues comparable to those of the previous year and the planned increase in operating expenses to fund expansion. The next observable milestone remains the Q4 2026 deadline, with the crossing of the €29.56 resistance as the next technical milestone.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2025
Guidance from the release
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
